Serum cholinesterase: function in lipoprotein metabolism.
Human serum beta-lipoproteins, isolated by percipitation with heparin-calcium mixture, showed cholinesterase activity. The enzyme activity was almost proportional to the lipoprotein concentration. Rats, treated with neostigmine, a cholinesterase inhibitor, showed a significant decrease in serum beta-lipoprotein and in the incorporation of H3-lysine into the lipoprotein compared to untreated controls. The decreased incorporation of H3-lysine into beta-lipoprotein was associated with increased labelling of alpha-lopoprotein. There was no significant difference in the labelling of pre-beta-lipoprotein. We propose that LDL is formed from VLDL in the presence of cholinesterase.
D000818:Animals; D002802:Cholinesterases / Q000097:blood*; D006801:Humans; D007700:Kinetics; D008074:Lipoproteins / Q000097:blood*; D008077:Lipoproteins, LDL / Q000096:biosynthesis / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D009388:Neostigmine / Q000494:pharmacology; D051381:Rats
D008074:Lipoproteins; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D009388:Neostigmine; D002802:Cholinesterases